Why Exact Sciences Fell 18% in September and Continues to Drop in October
Exact Sciences shares are falling sharply on worries that demand for its colon cancer-screening test will fall shy of predictions.
Investors took off exposure to Exact Sciences (NASDAQ:EXAS) in September ahead of a key update to colon cancer screening and that decision appears to have been the right one given that guidelines announced this month failed to include Exact Sciences' Cologuard.
In the following slideshow, you'll learn why this update to guidelines was important for Exact Sciences and the risks that its investors continue to face.